COMMUNIQUÉS West-GlobeNewswire

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
26/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
26/02/2026
SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III [...]
Premier Health Reports 2026 First Quarter Results
25/02/2026
MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
ACTG Announces Publication of STOMP Results in the New England Journal of Medicine
25/02/2026
Study findings do not support routine use of tecovirimat in people with mpox CHAPEL HILL, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, [...]
LENSAR® Provides Update on Pending Acquisition by Alcon
25/02/2026
ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
LifeStance Health Group Announces Launch of Secondary Public Offering
25/02/2026
SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
Bright Minds Biosciences to Present at Upcoming Conferences
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the [...]
Information on the total number of voting rights and shares
25/02/2026
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Informations sur le nombre total de droits de vote et d'actions
25/02/2026
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 25 février 2026, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
Pennant Reports Fourth Quarter and Fiscal Year 2025 Results
25/02/2026
Conference Call and Webcast scheduled for tomorrow, February 26, 2026 at 10:00 am MT EAGLE, Idaho, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Chemed Reports Fourth-Quarter 2025 Results
25/02/2026
CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation [...]
NANOBIOTIX to Participate in Investor Conferences in March
25/02/2026
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “ Company ”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
NANOBIOTIX participera à plusieurs conférences investisseurs en mars
25/02/2026
PARIS et CAMBRIDGE, Mass., 25 févr. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
25/02/2026
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE ® ( [...]
Korro to Present at the TD Cowen 46th Annual Health Care Conference
25/02/2026
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent [...]
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
25/02/2026
ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments [...]
OraSure Announces Fourth Quarter 2025 Financial Results
25/02/2026
BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
25/02/2026
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported [...]

Pages